6DAI J, WEINBERG R S, WAXMAN S, et al. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system [J]. Blood, 1999; 93: 268-277.
7GRAD J M, BAHLIS N J, REIS I, et al. Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells[J]. Blood, 2001, 98: 805-813.
8PEDERSEN L M, KLAUSEN T W, DAVIDSEN U H, et al. Early changes in serum IL-6 and VEGF levels predict clinical outcome following first line therapy in aggressive non-Hodgkin's lymphoma[J]. Ann Hematol, 2005,84: 510-516.
9NIITSU N, OKAMATO M, NAKAMINE H, et al. Simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleukin-6 as independent predictors of prognosis in aggressive non- Hodgkin'lymphoma[J]. Eur J Haematol, 2002, 68: 91-100.
10SALVEN P, ORPANA A, TEERNHOVI L. Simultaneous elevation in the serum concentration8 of the angiogenic growth factors VEGF and bFGF is an independent predictors of poor prognosis in non-Hodgkin lym-phoma : a single institution study of 200 patients [J]. Blood, 2000, 96: 3712-3718.
4Rashidi A, Silverberg ML, Conkling PR, et al. Thrombosis in acute promyelocytic leukemia[J]. Thromb Res,2013,131(4):281-289.
5Mi JQ, Li JM, Shen ZX, et al.How to manage acute promyelocytic leukemia [J].Leukemia, 2012,26(8):1743-1751.
6Grisariu S, Spectre G, Kalish Y, et al. Increased risk of central vcnouscathetcr-associated thrombosis in acute promyelocytic leukemia: a single-institution experience[J]. Eur J Haematol,2013, 90(5): 397-403.
